Remove Clinical Research Remove Clinical Trials Remove Therapies
article thumbnail

AI digital twins could replace control arm in clinical trials

Drug Discovery World

A new study demonstrates that AI-powered digital twin solutions can potentially replace the standard-of-care (SOC) control arm of a clinical trial. Diana Spencer, Senior Digital Content Editor, DDW The post AI digital twins could replace control arm in clinical trials appeared first on Drug Discovery World (DDW).

article thumbnail

First UK patients receive experimental mRNA therapy for cancer

Drug Discovery World

The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The study will assess the therapy administered alone or in combination with immune checkpoint inhibitor pembrolizumab.

Therapies 278
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How precision medicine will transform clinical trials

Drug Discovery World

Leveraging historical trial databases has become commonplace in assessing the feasibility of trials in therapeutic areas with a large breadth of clinical development history. EHR data also has a key role to play in designing future clinical trials.

article thumbnail

The need for greater diversity in clinical trials  

Drug Discovery World

Clinical trials are, undoubtedly, an essential part of the drug development process, providing us with valuable information about the safety and efficacy of new treatments and therapies. of participants 2 Covid-19 vaccination trials. In fact, these demographics which make up 13.8%

article thumbnail

Encouraging results for RESP-X in ongoing Phase I clinical trial

Drug Discovery World

RESP-X, Infex Therapeutics’ anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients, has shown a promising interim safety and tolerability profile in its ongoing first-in-human Phase I clinical trial.

article thumbnail

Interest in collagen-related therapeutics grows as clinical trials increase

Drug Discovery World

A new report reveals steadily growing interest in the clinical applications of collagen over the last 10 years. . Data analytics company Phesi analysed 2,358 clinical trials involving collagen. In the first 10 months of 2022, there were more than 225 new trials, compared with 125 in 2012.

article thumbnail

Improving Diversity: Increased Patient Access to Clinical Trials

Vial

The success of clinical trials hinges on increasing access to participation by all eligible patients, including populations that have been underrepresented due to the barriers highlighted below. Specifically, U.S. Patients underlined the need for transparency by pharma and other related companies to build trust and partnership.